NewAmsterdam Pharma N.V. (NAMS)
Bid | 14.34 |
Market Cap | 2.12B |
Revenue (ttm) | 45.31M |
Net Income (ttm) | -232.13M |
EPS (ttm) | -2.56 |
PE Ratio (ttm) | -7.37 |
Forward PE | -11.65 |
Analyst | Buy |
Ask | 23.98 |
Volume | 1,079,177 |
Avg. Volume (20D) | 976,960 |
Open | 20.06 |
Previous Close | 20.24 |
Day's Range | 18.53 - 20.06 |
52-Week Range | 14.06 - 27.29 |
Beta | 0.01 |
About NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein ...
Analyst Forecast
According to 7 analyst ratings, the average rating for NAMS stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 122.69% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibNew Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to fi...

2 months ago · seekingalpha.com
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol RevolutionNewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor failures...